Venetoclax in Combination With ASTX727
Venetoclax in Combination With ASTX727, an All-ORal Therapy for Chronic Myelomonocytic Leukemia and Other MDS/MPN With Excess Blasts (VICTORY-MDS/MPN): A Randomized, Phase 2 Trial
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 120 patients (estimated)
- Sponsors
- National Cancer Institute (NCI)
- Tags
- BCL-2 Inhibitor, Chemotherapy, Hypomethylating Agents (HMA)
- Trial Type
- Treatment
- Last Update
- 1 week ago
- SparkCures ID
- 1542
- NCT Identifier
- NCT05600894
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.